Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator

By Mederi Therapeutics Inc., PRNE
Sunday, January 30, 2011

GREENWICH, Connecticut, January 31, 2011 - Mederi Therapeutics Inc. announced today that it has received FDA 510(k)
clearance for its new MDRF1 Generator.

The Mederi RF Generator powers the Stretta(R) System for treatment of
Gastroesophageal Reflux Disease (GERD) as well as the Secca(R) System for
Bowel Incontinence or Bowel Control Disorder (BCD).

"Today's FDA clearance of the MDRF1 is the culmination of significant
investment and design efforts by Mederi. The goal of the MDRF1 project was to
produce a system of the highest quality and reliability to treat these two
serious and debilitating conditions," stated Will Rutan, Mederi's CEO.
"Mederi's new RF generator dramatically reduces the user's capital spending
requirements by combining two power generators into one. The MDRF1 is a
smaller, lighter and highly portable radiofrequency generator with a more
intuitive user interface than its predecessors," continued Rutan. "The MDRF1
combines the functionality of these earlier models into one system that
powers both the Stretta and Secca devices."

The availability of these products represents a significant advancement
in minimally invasive options for the millions of people who suffer from GERD
or BCD. The treatments involve delivery of radiofrequency energy to the
sphincter muscles at either end of the digestive system. Both Secca and
Stretta bridge the gap between conservative or pharmacologic therapy and
invasive surgery - giving doctors and patients an effective and less
complicated alternative.

This FDA 510(k) clearance, as well as our recently awarded CE Mark, and
ISO 13485 certification, demonstrate Mederi's steadfast commitment to
innovation, safety and quality.

Additional information is available at


Mederi Therapeutics manufactures and markets innovative medical devices
that deliver radiofrequency energy to treat disease states affecting the
human digestive system. All Mederi therapies are outpatient, minimally
invasive, and promote rapid recovery. Mederi Therapeutics is located in
Greenwich, Connecticut.

    Contact: Sheila Doyle, Manager of Communications and Marketing

Sheila Doyle, Manager of Communications and Marketing, +1-203-930-9980

will not be displayed